Description

Reta Vial — Triple GIP/GLP-1/Glucagon Receptor Agonist for Comprehensive Metabolic Research (32mg)

What is Reta?

Reta is a novel triple-hormone receptor agonist peptide that simultaneously activates three distinct receptor systems: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This triple-action mechanism is achieved through a single rationally designed peptide, making Reta one of the most comprehensive multi-receptor research tools available for metabolic signalling studies.

The development of Reta represents a significant advance in peptide engineering. By balancing the relative activity at each of the three receptors through careful sequence design, the peptide achieves meaningful activation at all three target sites. This is fundamentally different from mixing individual peptides — the single-molecule approach ensures consistent stoichiometry and allows researchers to study the integrated effects of triple-receptor activation as a unified signalling input.

Triple Receptor Pharmacology

• GIP Receptor (GIPR): A class B GPCR expressed on pancreatic beta cells, adipocytes, and in the central nervous system. GIPR signalling through cAMP/PKA pathways is associated with incretin effects on hormone secretion and lipid metabolism signalling.
• GLP-1 Receptor (GLP-1R): The classical incretin receptor, expressed on beta cells, neurons, and gastrointestinal tissue. GLP-1R activation influences appetite signalling, gastric motility, and glucose-dependent hormone release.
• Glucagon Receptor (GCGR): A class B GPCR primarily expressed in the liver, kidneys, and certain brain regions. GCGR activation stimulates glycogenolysis, gluconeogenesis, and energy expenditure pathways — providing a catabolic signalling component alongside the anabolic/anorectic incretin pathways.

The simultaneous activation of three receptors creates a complex signalling environment where the net cellular effect is determined by the relative contribution of each pathway, receptor density in target tissues, and downstream cross-talk between signalling cascades.

Research Applications

• Triple-Agonist Pharmacology: Characterising the integrated cellular response to simultaneous activation of three distinct GPCR systems.
• Energy Balance Research: Studying how incretin (GIP/GLP-1) and counter-regulatory (glucagon) pathways interact to influence overall energy metabolism.
• Multi-Receptor Signalling Networks: Investigating cross-talk between GIPR, GLP-1R, and GCGR signalling cascades in relevant tissue models.
• Comparative Receptor Studies: Comparing triple-agonist effects against dual-agonist and single-agonist approaches to isolate pathway-specific contributions.
• Target Expression Studies: Researching how triple-receptor activation affects receptor expression, desensitisation, and internalisation dynamics across different tissue types.

Product Description

Each vial contains 32mg of lyophilised Reta peptide as a sterile, freeze-dried preparation. The peptide is supplied in an individually sealed glass vial designed to maintain integrity during transport and storage. The lyophilised form requires reconstitution prior to laboratory use.

The white to off-white lyophilised powder is manufactured under controlled laboratory conditions with quality testing to verify purity and peptide content.

Product Specifications

• Compound: Reta (Triple GIP/GLP-1/Glucagon Receptor Agonist)
• Activity Profile: Balanced agonism at GIPR, GLP-1R, and GCGR
• Quantity: 32mg per vial
• Purity: ≥98% (HPLC verified)
• Form: Lyophilised sterile powder
• Packaging: Individually sealed, sterile glass vial
• Storage: 2-8°C (refrigerated). Protect from light and moisture.

What’s Included

Each order includes 1 × 3ml Bacteriostatic Water (BAC Water) for reconstituting the lyophilised powder. No additional reconstitution solution is required.

Key Research Benefits

• Triple Receptor Agonism: GIP, GLP-1 and glucagon receptor activation in a single research peptide.
• Energy Balance Studies: Anabolic incretin + catabolic glucagon pathways for metabolic research.
• Multi-Receptor Cross-Talk: Investigates GPCR signalling network interactions across tissue models.
• Comprehensive Tool: First-line research peptide for integrated metabolic signalling studies.

Reconstitution Guidelines

For experienced laboratory personnel only. This lyophilised powder must be reconstituted with bacteriostatic water prior to research use.

• Allow the vial to equilibrate to room temperature (15–25°C) before reconstitution.
• Wipe the rubber stopper with an alcohol swab and allow it to dry.
• Using a sterile syringe, add the required volume of Bacteriostatic Water by injecting slowly down the inner wall of the vial — do not aim the stream directly at the lyophilised cake.
• Gently swirl the vial until the powder is fully dissolved. Do not shake vigorously, as this can denature the peptide.
• Visually inspect the reconstituted solution — it should be clear and free of particulate matter.
• Store reconstituted solutions at 2–8°C and use within the timeframe defined in your research protocol. Discard any unused solution after the recommended period.

Important Notice

This product is for research and laboratory purposes only. Not for human or veterinary consumption. Not for medical use. Not evaluated by SAHPRA. Information is for educational reference only. Researchers must comply with all applicable laws, regulations, and institutional research guidelines.